ECFS statement on theratyping and theranostics in the context of rare and ultrarare CFTR variants in people with CF
Lab tests of patient cells could expand access to breakthrough cystic fibrosis drugs to people with rare genetic variants currently excluded from approved treatments.
The European Cystic Fibrosis Society consensus statement from 16 CF experts across Europe and North America advocates for theranostic approaches (patient-derived organoids, nasal epithelial cells) as essential tools for expanding access to highly effective CFTR modulators (ETI/VTD) to people with CF who carry rare/ultrarare variants not covered by current genotype-based approvals. The statement calls for regulatory integration of functional assays as standalone evidence of drug efficacy, addressing a significant equity gap for this subpopulation.
What the study was
- Study design
- Consensus statement with review of functional assay evidence
- Population
- People with cystic fibrosis carrying rare/ultrarare CFTR variants not covered by current genotype-based approvals
- Category
- Drug Development
- Maturity
- Potentially Practice-Changing
- Journal
- Journal of Cystic Fibrosis
Why it surfaced
Consensus statement from ECFS (16 experts) advocating functional-assay-based drug access for CF patients with rare CFTR variants — directly addresses equity gap in rare disease treatment access; ETI/VTD are highly effective and this expands potential beneficiaries.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.